Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys

M. Murphey-Corb, R. C. Montelaro, Mark Miller, M. West, L. N. Martin, B. Davison-Fairburn, S. Ohkawa, G. B. Baskin, J. Y. Zhang, G. B. Miller, S. D. Putney, A. C. Allison, D. A. Eppstein

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Immunization with an inactivated whole-virus vaccine is highly effective in preventing lentivirus infection. The viral protein(s) essential to the induction of protective responses, however, have not been identified. To define the role of virion components in the induction of protective immunity, we evaluated the efficacy of glycoprotein-enriched and glycoprotein-depleted simian immunodeficiency virus (SIV) subunit vaccines prepared by lentil-lectin affinity chromatography of gradient-purified virions using the immunization and challenge regimen previously found successful with an inactivated whole-virus vaccine. Infection was determined by successful recovery of virus, the induction of SIV-specific antibody responses, and infection of naive recipients by inoculation with lymph-node-derived lymphocytes from the vaccinates. Immunization with the glycoprotein-enriched preparation prevented infection in two out of four monkeys, whereas the glycoprotein-depleted vaccine failed to prevent infection in all four vaccinates tested. However, the glycoprotein-depleted vaccine appeared to moderate the progression of SIV-induced disease compared with non-immunized infected control monkeys inoculated with the same challenge dose. These data suggest that subunit vaccines containing sufficient quantities of viral glycoproteins can protect against SIV infection, whereas subunit vaccines composed predominantly of viral core proteins cannot. The development of effective vaccines against HIV infection should include studies on the optimum presentation of the viral envelope glycoproteins to produce long-term broadly protective immune responses.

Original languageEnglish (US)
Pages (from-to)655-662
Number of pages8
JournalAIDS
Volume5
Issue number6
DOIs
StatePublished - Jan 1 1991
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
Subunit Vaccines
Macaca mulatta
Glycoproteins
Vaccines
Infection
Immunization
Virus Diseases
Virion
Haplorhini
Lentivirus Infections
Viral Core Proteins
Viruses
Virus Activation
Viral Proteins
Affinity Chromatography
HIV Infections
Antibody Formation
Immunity
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. / Murphey-Corb, M.; Montelaro, R. C.; Miller, Mark; West, M.; Martin, L. N.; Davison-Fairburn, B.; Ohkawa, S.; Baskin, G. B.; Zhang, J. Y.; Miller, G. B.; Putney, S. D.; Allison, A. C.; Eppstein, D. A.

In: AIDS, Vol. 5, No. 6, 01.01.1991, p. 655-662.

Research output: Contribution to journalArticle

Murphey-Corb, M, Montelaro, RC, Miller, M, West, M, Martin, LN, Davison-Fairburn, B, Ohkawa, S, Baskin, GB, Zhang, JY, Miller, GB, Putney, SD, Allison, AC & Eppstein, DA 1991, 'Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys', AIDS, vol. 5, no. 6, pp. 655-662. https://doi.org/10.1097/00002030-199106000-00003
Murphey-Corb, M. ; Montelaro, R. C. ; Miller, Mark ; West, M. ; Martin, L. N. ; Davison-Fairburn, B. ; Ohkawa, S. ; Baskin, G. B. ; Zhang, J. Y. ; Miller, G. B. ; Putney, S. D. ; Allison, A. C. ; Eppstein, D. A. / Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys. In: AIDS. 1991 ; Vol. 5, No. 6. pp. 655-662.
@article{e5844017a0f144cda28793718d23dd2e,
title = "Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys",
abstract = "Immunization with an inactivated whole-virus vaccine is highly effective in preventing lentivirus infection. The viral protein(s) essential to the induction of protective responses, however, have not been identified. To define the role of virion components in the induction of protective immunity, we evaluated the efficacy of glycoprotein-enriched and glycoprotein-depleted simian immunodeficiency virus (SIV) subunit vaccines prepared by lentil-lectin affinity chromatography of gradient-purified virions using the immunization and challenge regimen previously found successful with an inactivated whole-virus vaccine. Infection was determined by successful recovery of virus, the induction of SIV-specific antibody responses, and infection of naive recipients by inoculation with lymph-node-derived lymphocytes from the vaccinates. Immunization with the glycoprotein-enriched preparation prevented infection in two out of four monkeys, whereas the glycoprotein-depleted vaccine failed to prevent infection in all four vaccinates tested. However, the glycoprotein-depleted vaccine appeared to moderate the progression of SIV-induced disease compared with non-immunized infected control monkeys inoculated with the same challenge dose. These data suggest that subunit vaccines containing sufficient quantities of viral glycoproteins can protect against SIV infection, whereas subunit vaccines composed predominantly of viral core proteins cannot. The development of effective vaccines against HIV infection should include studies on the optimum presentation of the viral envelope glycoproteins to produce long-term broadly protective immune responses.",
author = "M. Murphey-Corb and Montelaro, {R. C.} and Mark Miller and M. West and Martin, {L. N.} and B. Davison-Fairburn and S. Ohkawa and Baskin, {G. B.} and Zhang, {J. Y.} and Miller, {G. B.} and Putney, {S. D.} and Allison, {A. C.} and Eppstein, {D. A.}",
year = "1991",
month = "1",
day = "1",
doi = "10.1097/00002030-199106000-00003",
language = "English (US)",
volume = "5",
pages = "655--662",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Efficacy of SIV/D DeltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys

AU - Murphey-Corb, M.

AU - Montelaro, R. C.

AU - Miller, Mark

AU - West, M.

AU - Martin, L. N.

AU - Davison-Fairburn, B.

AU - Ohkawa, S.

AU - Baskin, G. B.

AU - Zhang, J. Y.

AU - Miller, G. B.

AU - Putney, S. D.

AU - Allison, A. C.

AU - Eppstein, D. A.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Immunization with an inactivated whole-virus vaccine is highly effective in preventing lentivirus infection. The viral protein(s) essential to the induction of protective responses, however, have not been identified. To define the role of virion components in the induction of protective immunity, we evaluated the efficacy of glycoprotein-enriched and glycoprotein-depleted simian immunodeficiency virus (SIV) subunit vaccines prepared by lentil-lectin affinity chromatography of gradient-purified virions using the immunization and challenge regimen previously found successful with an inactivated whole-virus vaccine. Infection was determined by successful recovery of virus, the induction of SIV-specific antibody responses, and infection of naive recipients by inoculation with lymph-node-derived lymphocytes from the vaccinates. Immunization with the glycoprotein-enriched preparation prevented infection in two out of four monkeys, whereas the glycoprotein-depleted vaccine failed to prevent infection in all four vaccinates tested. However, the glycoprotein-depleted vaccine appeared to moderate the progression of SIV-induced disease compared with non-immunized infected control monkeys inoculated with the same challenge dose. These data suggest that subunit vaccines containing sufficient quantities of viral glycoproteins can protect against SIV infection, whereas subunit vaccines composed predominantly of viral core proteins cannot. The development of effective vaccines against HIV infection should include studies on the optimum presentation of the viral envelope glycoproteins to produce long-term broadly protective immune responses.

AB - Immunization with an inactivated whole-virus vaccine is highly effective in preventing lentivirus infection. The viral protein(s) essential to the induction of protective responses, however, have not been identified. To define the role of virion components in the induction of protective immunity, we evaluated the efficacy of glycoprotein-enriched and glycoprotein-depleted simian immunodeficiency virus (SIV) subunit vaccines prepared by lentil-lectin affinity chromatography of gradient-purified virions using the immunization and challenge regimen previously found successful with an inactivated whole-virus vaccine. Infection was determined by successful recovery of virus, the induction of SIV-specific antibody responses, and infection of naive recipients by inoculation with lymph-node-derived lymphocytes from the vaccinates. Immunization with the glycoprotein-enriched preparation prevented infection in two out of four monkeys, whereas the glycoprotein-depleted vaccine failed to prevent infection in all four vaccinates tested. However, the glycoprotein-depleted vaccine appeared to moderate the progression of SIV-induced disease compared with non-immunized infected control monkeys inoculated with the same challenge dose. These data suggest that subunit vaccines containing sufficient quantities of viral glycoproteins can protect against SIV infection, whereas subunit vaccines composed predominantly of viral core proteins cannot. The development of effective vaccines against HIV infection should include studies on the optimum presentation of the viral envelope glycoproteins to produce long-term broadly protective immune responses.

UR - http://www.scopus.com/inward/record.url?scp=0025922119&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025922119&partnerID=8YFLogxK

U2 - 10.1097/00002030-199106000-00003

DO - 10.1097/00002030-199106000-00003

M3 - Article

VL - 5

SP - 655

EP - 662

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 6

ER -